FDA approves Neuralstem Phase II amytrophic lateral sclerosis trial
The dose escalation and safety trial will expand to two centres in Atlanta and Ann Arbor, subject to approval by the Institutional Review Board at each institution. Neuralstem
SK bioscience is set to lead the Gates Foundation-fundedResearch Optimization & Trial Outcome Recommender (ROTOR) project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.
In pre-clinical asthma models ASM-024 exhibited the capabilities of inhibitory effects on inflammation, bronchoprotection and smooth muscle relaxation. Asmacure founder and chief medical officer Yvon Cormier said the